Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

rhIL‑7-hyFc was not associated with improved survival in the overall cohort but was associated with improved survival in older patients. Adding rhIL‑7-hyFc, a long-acting IL-7, to treatment with ...

Adding TTFields to first-line treatment with temozolomide and radiotherapy improved progression-free survival in patients with glioblastoma.

More than three-quarters of evaluable patients had a tumor-associated antigen-specific immune response. CVGBM, an investigational cancer vaccine, induced immune responses in more than three-quarters ...

The disease control rate was 92%, and the median progression-free survival was 13.7 months. Treatment with 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and pembrolizumab appeared well ...

Patients with recurrent glioblastoma may derive a greater benefit from sacituzumab govitecan if they have high TROP2 expression.

Pre-operative fractionated stereotactic radiotherapy (FSRT) may produce better outcomes than post-operative FSRT in cancer patients with brain metastases.

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — ...